Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review

Vonk, Lucienne A.; de Windt, Tommy S.; Slaper-Cortenbach, Ineke C. M.; Saris, Daniël B. F.

doi:10.1186/s13287-015-0086-1

Stem Cell Research & Therapy

Table 1 Overview of clinical studies applying autologous mesenchymal stromal cells to a cartilage defect

From: Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review

Cell type	Study type	Number of patients	Follow-up	Results	Reference
BMMSC	Case report	2	5 years	Clinical improvement and defect fill with fibrocartilage	[25]
BMMSC	Case report	1	1 year	Bone and cartilage repair	[26]
BMMSC	Case report	3	17-27 months	Clinical improvement and defect fill with fibrocartilage	[27]
BMMSC	Case report	1	12 months	Clinical improvement and defect fill with hyaline tissue	[28]
BMMSC	Case series	5	12 months	Clinical improvement and defect fill	[29]
BMMSC	Case report	2	31 months	Clinical improvement and defect fill	[30]
BMC	Case series	48	4 years	Clinical improvement and defect fill	[31,32]
BMC	Case series	20	24 months	Bone and cartilage repair	[33]
BMC	Case series	5	12 months	Defect fill with hyaline to fibrocartilaginous tissue	[34]
BMC	Case series	54	5 years	Clinical improvement and good integration of repair tissue	[35]
BMC	Case series	15	2 years	Clinical improvement and defect fill with hyaline tissue	[36]
BMC and ACy	Case series	40	Interim results 1 year	Clinical improvement and defect fill with hyaline tissue	[37] NCT01041885
SMSC					[16,17]
BMMSC	Comparative study	36 (total 72)	24 months	Clinical improvement, defect fill with hyaline tissue	[38]
BMC	Comparative study	25 (total 81)	36 months	Clinical improvement and defect fill with hyaline tissue	[39]
PBMSC or BMC	Comparative study	25 PBMSC, 21 BMC	5 years	Clinical improvement and defect fill for both groups	[40]
BMMSC	Case series	25	12 months		NCT00891501
BMMSC	Case series	6	12 months		NCT00850187
BMC	Case series	140	36 months		NCT02005861
BMC	Case series	50	12 months		NCT01159899
ATSVF	Comparative study	40	24 months		NCT02090140
ATMSC	Comparative study	30	18 months		NCT01399749
BMMSC	Comparative study	50 in total	5 years		NCT00885729

ACy autologous chondrocyte, ATMSC adipose tissue-derived mesenchymal stromal cell, ATSVF adipose tissue stromal vascular fraction, BMC bone marrow concentrate, BMMSC bone marrow-derived mesenchymal stromal cell, PBMSC peripheral blood-derived mesenchymal stromal cell, SMSC synovium-derived mesenchymal stromal cell

Back to article page

ISSN: 1757-6512

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com